Literature DB >> 26951081

Tumour infiltrating lymphocytes and stromal CD68 in early stage HER2 positive breast cancer.

Jacques Raphael1, I Y Gong2, S Nofech-Mozes3, Jms Bartlett4, H Nafisi3, S Verma1.   

Abstract

Entities:  

Keywords:  BREAST CANCER; CERB 2; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE MARKERS; MACROPHAGES

Mesh：

Substances：

Year:  2016        PMID： 26951081     DOI： 10.1136/jclinpath-2015-203493

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN： 0021-9746            Impact factor:   3.411


× No keyword cloud information.
  4 in total

1.  Expression and clinical prognostic value of CYB561 in breast cancer.

Authors:  Xiaofeng Zhou; GuoShuang Shen; Dengfeng Ren; Xinjian Guo; Jingqi Han; Qijing Guo; Fuxing Zhao; Miaozhou Wang; Qiuxia Dong; Zhanquan Li; Jiuda Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-29       Impact factor: 4.322

Review 2.  Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.

Authors:  Irina Larionova; Gulnara Tuguzbaeva; Anastasia Ponomaryova; Marina Stakheyeva; Nadezhda Cherdyntseva; Valentin Pavlov; Evgeniy Choinzonov; Julia Kzhyshkowska
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

3.  Prognostic Value of Tumor Infiltrating Lymphocytes in Locally Advanced HER2 Enriched Breast Cancer.

Authors:  Mostafa M Saber; Heba M El Zawahry; Amany M Hilal; Amany A Abou-Bakr; Alfred E Namour; Mona M Saber
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

4.  Identification of methylation-driven genes related to the prognosis of papillary renal cell carcinoma: a study based on The Cancer Genome Atlas.

Authors:  Zeyu Liu; Yuxiang Wan; Ming Yang; Xuewei Qi; Zhenzhen Dong; Jinchang Huang; Jingnan Xu
Journal:  Cancer Cell Int       Date:  2020-06-12       Impact factor: 5.722
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.